{
  "docId": "019de076-8183-75b8-8b2d-7503ba8c42ba",
  "docSlug": "f8cc3498a347f12db8c194c5955f1d44",
  "documentTitle": "Kymera | Investor Presentation Deck | 46 slides",
  "authorId": "kymera",
  "authorName": "Kymera Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 46,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 20,
  "notes": "Includes a mechanism of action diagram, a market data table, and a callout box on competitive limitations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8183-75b8-8b2d-7503ba8c42ba/9",
  "deckHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba",
  "deckJsonHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba.json",
  "deckAnchorHref": "/decks/019de076-8183-75b8-8b2d-7503ba8c42ba#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.55,
        "y": 0.62
      },
      "kind": "callout",
      "text": "Limitations of Current Therapies: Anti-Cytokine/Cytokine Receptor Antibodies and Small Molecule Inhibitors",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4783fe4-d991-456d-b0e0-c315677eab35",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.44,
        "x": 0.12,
        "y": 0.16
      },
      "kind": "diagram",
      "text": "Mechanism of action showing KT-474 inhibiting IRAK4",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16791ece-6974-4e63-bfcc-167a3970eb86",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.05,
        "y": 0.52
      },
      "kind": "list",
      "text": "Th1-Th17/Neutrophils and Th2/Eosinophils disease lists",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb9aaec4-dd7f-4574-892d-72ec0530bc29",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.06,
        "y": 0.78
      },
      "kind": "metric",
      "text": "~$120B Combined global drug sales",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f264a038-5e49-494f-9c33-eda8e055de0b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: 1. GlobalData; 2. Evaluate Pharma; 3. Ahn. JAMA Otolaryngol Head Neck Surg. 2016; 4. Dash. Allied Market Research 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f4b413d-3bb8-48a1-9940-c15db2257eae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.55,
        "y": 0.15
      },
      "kind": "table",
      "text": "Indication, Prevalence, and Global Sales table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e92e5dd-3df7-435b-b322-9842169d489e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.56,
        "x": 0.22,
        "y": 0.09
      },
      "kind": "title",
      "text": "Potential for Broad Activity Across Th1-Th17 and Th2 Diseases",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f7dead3-755e-48fb-acab-90dcf96e3ed7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.88,
        "x": 0.06,
        "y": 0.03
      },
      "kind": "title",
      "text": "IRAK4 Degrader Best-in-Class Potential in Immune-inflammation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "160ddb18-7649-4895-88cb-e2eb9af46d63",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "82114c8a-c1e6-4e74-ae22-2ba61d31d9e4",
      "evidence": "The slide contains a table/data with indication, prevalence, and global sales information.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "3821b163-197d-4c86-9367-33b4bd3fb93a",
      "arcName": "AIDA",
      "arcSlug": "aida",
      "beatName": "Desire",
      "beatSlug": "aida-desire",
      "evidence": "The deck showcases the potential for broad activity across multiple diseases, creating desire for Kymera's TPD approach.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 5,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "7b376215-a5b5-4891-ad20-1901edfeffd7",
      "evidence": "The deck presents a clear logical chain from the problem to the solution and potential benefits.",
      "position": 0,
      "objective": "To demonstrate the logic and potential of Kymera's TPD approach",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    },
    {
      "to": 20,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4c55e1a3-cbe4-4bd4-91f4-d237841a6ee0",
      "evidence": "The deck implies the limitations of current treatments and the potential consequences of not adopting new approaches.",
      "position": 1,
      "objective": "To highlight the cost of inaction and the need for new treatments",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}